• Orange Regional Health Connection


  • Text Size:

  • Print:

  • Share:


Clinical Trials

Leukemia Protocols

Please check with your physician for additional protocols and/or information.


1.  E2905:  Randomized Phase III Trial Comparing the Frequency of Major Erythroid Alfa in Subjects with Low or Intermediate 1 Risk MDS and Symptomatic Anemia

The purpose of this study is to compare how a drug called lenalidomide affects (good or bad) you and your condition when given alone compared with when given with another drug called epoetin alfa (Procrit). We want to find out which is better. Epoetin alfa (Procrit) boosts the production of red blood cells. Lenalidomide makes early red blood cells more likely to be affected by the growth promoting effects of epoetin alfa (Procrit) and other red blood cell hormones. This study is being done to determine if the combination of treatment with epoetin alfa (Procrit) and lenalidomide is better than lenalidomide alone in improving red blood cell production and in relieving the need for red blood cell transfusions in patients with MDS (myelodysplastic syndrome). In this study, you will get either lenalidomide or lenalidomide and epoetin alfa (Procrit). If you get lenalidomide alone and it does not have a very good effect on you after 4 cycles, then you will be offered lenalidomide and epoetin alfa (Procrit).

2. S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

The purpose of this study is to compare the effects, good and/or bad on your and your MDS or CMML, of adding either the drug lenalidomide or the drug vorinostat to the regular treatment drug azacitidine.  In this study, you will be on one of the following treatment arms:  azacitidine alone, azacitidine and lenalidomide or azacitidine and vorinostat.  You will only get one of these treatments.

3.  E1912:  A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and Ibrutinib have on you and your CLL. The first three of these drugs are standard treatments for CLL. Fludarabine and cyclophosphamide have been approved by the Food and Drug Administration (FDA) for the treatment of CLL. Rituximab is approved for the treatment of CLL when given in combination with fludarabine and cyclophosphamide and is also approved for treatment of non-Hodgkin lymphoma and rheumatoid arthritis. Ibrutinib has been previously studied in patients with CLL, and has been approved by the FDA for use in previously treated CLL patients. In this study, ibrutinib is investigational because it will be given to previously untreated CLL patients and administered in combination with rituximab.

For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133.

Orange Regional Medical Center
707 East Main Street
Middletown, NY 10940

Directions »

Orange Regional Medical Pavilion
75 Crystal Run Road
Middletown, NY 10940

Directions »
Join Our Email List
For Medical Staff
For Employees
Disclaimer | Privacy Policy | Sitemap | Locations

Copyright © 2014 Orange Regional Medical Center
Joint Commission National Quality Approved
A member of the Greater Hudson Valley Health System